Merck & Co. Inc. (NYSE:MRK) has signed a deal with Endocyte to develop and commercialize the cancer drug vintafolide.
Merck & Co. Inc. Signs Cancer Drug Deal
Merck & Co. Inc. (NYSE:MRK) has announced that it has entered into an agreement with Endocyte to develop and commercialize Endocyte’s investigational therapeutic candidate vintafolide (EC145).
Merck, through a subsidiary, will gain worldwide rights to develop and commercialize vintafolide.
Peter S. Kim, executive vice president and president Laboratories, said that, “Vintafolide is a promising and innovative late-stage cancer drug candidate. In addition to pursuing the lead indication of platinum-resistant ovarian cancer, Merck plans to further evaluate its potential for treatment of multiple other cancer types”.
Merck & Co. Inc. (NYSE:MRK) shares were at 37.95 at the end of the last day’s trading. There’s been a -1.4% change in the stock price over the past 3 months.